Loading stock data…
PROF
$6.82+0.25 (+3.81%)
After Hours$6.82+0.00 (+0.00%)· Last close Jun 9
Profound Medical Corp.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Profound Medical Corp. in the Healthcare sector is trading at $6.82 with a market capitalization of $242M. Wall Street consensus targets $11.14 (5 analysts), implying a +63.3% move over the next 12 months. The stock is currently 24% below its 52-week high of $8.95, remaining 6.7% above its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the safe zone. The Whystock Score of 100/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +63.3% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$6.82
Potential Downside
0%
Whystock Fair Value$6.82
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company's lead product TULSA-PRO sy...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$242.37M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-65.46%
Volume
Today's trading volume
60,707
Recent News
Wall Street Analysts See a 59.68% Upside in Profound Medical (PROF): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 59.7% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Profound Medical Q1 Earnings Call Highlights
Profound Medical (NASDAQ:PROF) reported sharply higher first-quarter revenue and reiterated its view that adoption of its TULSA prostate treatment platform is moving toward broader commercial use, supported by new clinical data, payer progress and a growing installed base. For the three months ende
Profound Medical (PROF) Reports Q1 Loss, Tops Revenue Estimates
Profound Medical (PROF) delivered earnings and revenue surprises of +21.91% and +4.79%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Profound Medical Down 8.5% After Hours as Its Q1 Loss Narrows, Revenue More Than Doubles, Beats Estimates
Profound Medical (PRN.TO, PROF) was last seen down 8.5%% in after-hours New York trade after the com
Profound Medical Corp. (TSE:PRN) Is Expected To Breakeven In The Near Future
Profound Medical Corp. ( TSE:PRN ) is possibly approaching a major achievement in its business, so we would like to...